Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

Phase 1 Completed 50 enrolled Threshold Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced solid tumors.

Timeline

Start: 2004-02
Primary completion: 2008-07
Completion: 2008-07

Publications

Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Feb;71(2):523-30. doi: 10.1007/s00280-012-2045-1. Epub 2012 Dec 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	2-Deoxy-D-Glucose	Small molecule	2 mg/kg	Oral
Subject	2-Deoxy-D-Glucose	Small molecule	63 mg/kg	Oral
Subject	2-Deoxy-D-Glucose	Small molecule	88 mg/kg	Oral

Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications